Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 18/20 | 0.80 |
| ▸ | EPHB4 | P54760 | 12/20 | 0.80 |
| ▸ | KDR | P35968 | 15/20 | 0.73 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.73 |
| ▸ | FLT1 | P17948 | 13/20 | 0.71 |
| ▸ | EGFR | P00533 | 1/20 | 0.68 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.68 |
| ▸ | FLT4 | P35916 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL906884 | 0.89 | EPHA2 (1.00) | EPHA2EPHB4KDRERBB2FLT1 | |
| SCHEMBL14095979 | 0.87 | EPHA2 (0.82) | EPHA2EPHB4KDRERBB2FLT1 | |
| SCHEMBL906941 | 0.84 | EPHA2 (1.00) | EPHA2EPHB4KDRERBB2FLT1 | |
| SCHEMBL5446461 | 0.84 | EPHA2 (0.79) | EPHA2EPHB4KDRFLT1EGFR | |
| SCHEMBL1224764 | 0.83 | ERBB2 (1.00) | EPHA2EPHB4KDRERBB2FLT1 | |
| SCHEMBL1225525 | 0.83 | EPHA2 (1.00) | EPHA2EPHB4KDRERBB2EGFR | |
| SCHEMBL1225302 | 0.83 | EPHA2 (1.00) | EPHA2EPHB4KDRERBB2FLT1 | |
| Hydrochloric Acid SCHEMBL907918 | 0.83 | ERBB2 (0.99) | EPHA2EPHB4KDRERBB2FLT1 | |
| Hydrochloric Acid SCHEMBL907920 | 0.83 | ERBB2 (0.99) | EPHA2EPHB4KDRERBB2FLT1 | |
| SCHEMBL906990 | 0.82 | ERBB2 (1.00) | EPHA2EPHB4KDRERBB2FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080199480-A1 | Methods for Identifying Risk of Type II Diabetes and Treatments Thereof | SEQUENOM, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080199480-A1 | Methods for Identifying Risk of Type II Diabetes and Treatments Thereof | SEQUENOM, INC. (US) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080199480-A1 | Methods for Identifying Risk of Type II Diabetes and Treatments Thereof | SLC5A2, GCKR, IAPP | EPHA2 805/4885EPHB4 1038/4885KDR 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.